Navigation Links
Taligen Therapeutics Secures Series B Financing
Date:2/1/2008

AURORA, Colo., Feb. 1 /PRNewswire/ -- Taligen Therapeutics, Inc. today announced it anticipates receiving up to $65 million in a tranched Series B financing. The financing was led by Alta Partners and Clarus Ventures with participation from existing investors, including Sanderling Ventures, Tango and High Country Venture.

"This Series B round represents not only an infusion of capital but the addition of two world class investor groups, Alta Partners and Clarus Ventures, represented on our Board respectively by Edward Hurwitz and Nicholas Galakatos, PhD," said Timothy Mills, PhD, Chairman of the Board of Taligen. "The progress made since our original investment in 2005 now allows us to develop multiple products to control the alternative pathway of complement activation. With this additional funding, we expect to move into clinical development with all of our lead candidates."

About Taligen: Founded in 2004, Taligen Therapeutics, Inc. is a development-stage biotechnology company with novel technology and expertise focused on modulation and control of the complement system. The complement system is believed to be a critical component in the initiation of inflammation. Complement system activation is characteristic of many human diseases, including asthma, macular degeneration, rheumatoid arthritis and immune renal disease.

Taligen's lead products are monoclonal antibodies and recombinant fusion proteins which target key factors in the alternative complement pathway. These products are in preclinical stages of development to treat systemic as well as local inflammatory conditions.

The Company was founded by Drs. Woodruff Emlen and V. Michael Holers based on technology and intellectual property predominantly from the University of Colorado at Denver and Health Sciences Center (UCDHSC) and partnering institutions. Dr. Holers is currently Professor of Medicine at UCDHSC and Dr. Emlen is a former Professor of Medicine and Immunology at U
'/>"/>

SOURCE Taligen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
2. CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008
3. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
4. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
5. CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
6. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
10. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
11. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2015)... ... July 06, 2015 , ... For many years, metal-on-quartz filters ... a high-end machine such as a Varian Cary 4000-7000, a Perkin Elmer 800-1100 or ... design that even NIST used them for their SRM-2031 series going back for many ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... ... highly-regarded by Fortune 500 companies and professional service industries alike-- typically known for ... make clients laugh, honor a good cause and break from their day jobs. ...
(Date:7/3/2015)... Forskere kan søke ... Science", som finner sted i ... på  http://www.openinnovationinscience.at , og søknadsperioden varer frem ... to største utfordringene innen helsevitenskapen er mangelen ... og kompleksiteten av nåværende forskningsresultater, i følge ...
(Date:7/2/2015)... ... July 03, 2015 , ... Cuvettes have been used in countless labs for decades. ... the cuvette they needed. As expected, this was a daunting and tiring process looking ... because they were not able to navigate the complex catalog structure. , Now thanks to ...
Breaking Biology Technology:FireflySci Simplifies the Calibration of UV Spectrophotometers with FUV Photometric Accuracy Standards 2FireflySci Simplifies the Calibration of UV Spectrophotometers with FUV Photometric Accuracy Standards 3The Alexander Group Declares Their Independence with a Bit of Levity 2Lansering av verdens første Open Innovation-program for utdanning av forskere 2Lansering av verdens første Open Innovation-program for utdanning av forskere 3New Cuvette E-Commerce Website Launched by FireflySci 2
... the Cost of Genome Analysis to $100 In ... Routine Medical Care-PHILADELPHIA, Feb. 24 BioNanomatrix, Inc., ... analysis platforms for biomedical research, molecular diagnostics and ... genome analysis technology, along with founder and chief ...
... Gene Network Sciences, Inc. (GNS) today announced that it ... Officer of Stromedix, Inc. and former Executive Vice President ... Directors. Dr. Gilman has been Founder and Chief ... was previously Executive Vice President, Research at Biogen Idec. ...
... PharmAthene, Inc. (NYSE Alternext US: PIP), a biodefense ... threats, announced today that results from a Phase ... for Valortim(R) were presented at the 7th Annual ... held in Baltimore, MD, February 22-25, 2009. David ...
Cached Biology Technology:BioNanomatrix's Revolutionary Whole Genome Analysis Platform Named to MIT Technology Review's Annual 10 Emerging Technologies List 2BioNanomatrix's Revolutionary Whole Genome Analysis Platform Named to MIT Technology Review's Annual 10 Emerging Technologies List 3Gene Network Sciences Announces Michael Gilman as Board Member 2PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 2PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 3PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 4PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 5PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 6PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 7
(Date:6/17/2015)... Maryland , and HILDEN, Germany , ... QGEN ; Frankfurt Prime Standard: QIA) today launched new ... evidence in forensic laboratories in the United States ... solution to simultaneously analyze multiple key genomic markers (short tandem ... ® Quality Sensor to evaluate the quality of DNA ...
(Date:6/16/2015)... , June 16, 2015 Fingerprint ... touch fingerprint sensors in the company,s portfolio from one of ... are planned to mainly take place during the third quarter ... Asia . Jörgen Lantto, CEO ... of    the   growing interest from smartphone OEMs in ...
(Date:6/12/2015)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announced the United States Patent ... and identify participants of a video visitation session ... system can: , Identify that the ... process is actually the person participating in the ...
Breaking Biology News(10 mins):QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2
... the leading cause of blindness in western society, say experts ... a new eye instrument, they have launched a study to ... strength could also explain why the 77-year-old sailor has no ... sweetcorn, kale and broccoli are rich in a chemical called ...
... virtually any other type of therapy, has given rise ... also great concerns regarding health risks. Since the Deutsche ... in 1995, this field of research has developed enormously. ... as well as the risks of gene therapy. The ...
... to accurately distinguish benign from malignant breast lesions. ... and harmless lesions in nearly all of the ... the annual meeting of the Radiological Society of ... imaging has been found to have high specificity,?said ...
Cached Biology News:Why Popeye only has eyes for spinach 2Development of gene therapy 2Elasticity imaging identifies cancers and reduces breast biopsies 2
The improved design and new mechanical solutions of Finnpipette Focus Multichannel Plus improves accuracy and precision.In these low volume multichannel pipettes, the super blow-out function ensures ...
NAK/TBK1 (CT) Affinity Purified Polyclonal Antibody...
... White lyophilized solid. PROTECT FROM ... reversible inhibitor of γ-secretase. Equipotently inhibits the ... = 2.6 μM) and Aβ x-42 ... in HEK293 cells stably transfected with the ...
...
Biology Products: